2025年HFrEF的药理疗法:2025年HFrEF的药理疗法:2025年HFrEF的药理疗法:2025年HFrEF的药理疗法:2025年HFrEF的药理疗法:2025年HFrEF的药理疗法:2025年HFrEF的药理疗法:2025年
Massimo Mapelli1,2, Filippo Maria Rubbo1,3, Simona Costantino1
1Centro Cardiologico Monzino, IRCCS Milan, Italy.
Cardiac failure review
|August 7, 2025
概括
最近的心力衰竭与减少喷射率 (HFrEF) 治疗方法显示出有前途,建立在已确立的治疗方法上. 尽管在药物和设备方面取得了进展,但在管理这种广泛的疾病方面仍然存在挑战.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗技术 医疗技术 医学技术
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭显著影响全球健康,导致死亡率,发病率和生活质量下降.
- 已建立的治疗方法,如β-阻断剂和ACE抑制剂,构成了HFrEF管理的基础.
研究的目的:
- 审查HFrEF治疗的最新进展,包括新的药物和设备.
- 突出突出超越HFrEF治疗的基本四大支柱的创新.
- 讨论管理HFrEF的持续挑战.
主要方法:
- 对HFrEF治疗的最新发现的文献综述.
- 分析新的治疗策略和技术发展.
- 讨论当前的临床管理和未来的方向.
主要成果:
- 对HFrEF患者预后的显著改善归因于最近的医学治疗进展.
- 新的药物,设备和优化的利尿药疗法是最近的关键进展.
- 高FrEF处理的四个支柱是基本的,但不是详尽的.
结论:
- 最近的发展为改善HFrEF管理提供了乐观的希望.
- 在解决HFrEF的全球负担方面,仍然存在着未解决的挑战.
- 持续创新对于减轻与HFrEF相关的高成本和糟糕结果至关重要.
相关概念视频
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
509
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28
Cardiomyopathy V: Interprofessional Care
34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435


